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Abstract 
Background: In this study we explored the possibility of automating the PGP9.5 immunofluorescence staining 
assay for the diagnosis of small fiber neuropathy using skin punch biopsies. The laboratory developed test (LDT) was 
subjected to a validation strategy as required by good laboratory practice guidelines and compared to the well-
established gold standard method approved by the European Federation of Neurological Societies (EFNS). To facilitate 
automation, the use of thinner sections. (16 µm) was evaluated. Biopsies from previously published studies were 
used. The aim was to evaluate the diagnostic performance of the LDT compared to the gold standard. We focused on 
technical aspects to reach high-quality standardization of the PGP9.5 assay and finally evaluate its potential for use in 
large scale batch testing.
Results: We first studied linear nerve fiber densities in skin of healthy volunteers to establish reference ranges, and 
compared our LDT using the modifications to the EFNS counting rule to the gold standard in visualizing and quanti-
fying the epidermal nerve fiber network. As the LDT requires the use of 16 µm tissue sections, a higher incidence of 
intra-epidermal nerve fiber fragments and a lower incidence of secondary branches were detected. Nevertheless, the 
LDT showed excellent concordance with the gold standard method. Next, the diagnostic performance and yield of 
the LDT were explored and challenged to the gold standard using skin punch biopsies of capsaicin treated subjects, 
and patients with diabetic polyneuropathy. The LDT reached good agreement with the gold standard in identifying 
small fiber neuropathy. The reduction of section thickness from 50 to 16 µm resulted in a significantly lower visualiza-
tion of the three-dimensional epidermal nerve fiber network, as expected. However, the diagnostic performance of 
the LDT was adequate as characterized by a sensitivity and specificity of 80 and 64 %, respectively.
Conclusions: This study, designed as a proof of principle, indicated that the LDT is an accurate, robust and auto-
mated assay, which adequately and reliably identifies patients presenting with small fiber neuropathy, and therefore 
has potential for use in large scale clinical studies.
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Background
PGP9.5 immunostaining of intra-epidermal nerve fib-
ers in 50  µm sections is widely accepted as the gold 
standard for the diagnosis of small fiber neuropathy. 
The assay is used to visualize the number and morphol-
ogy of the somatic, small caliber, intra-epidermal nerve 
fibers, and supported by the European Federation of 
Neurological Societies (EFNS) [1]. The use of skin biop-
sies as a diagnostic tool in peripheral neuropathies has 
increased in the last decades, and is regarded as a reli-
able and standardized tool [1–7]. The Polyneuropathy 
Task Force [3] concluded that the gold standard was 
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diagnostically efficient at distinguishing polyneuropa-
thy patients [including small fiber neuropathy (SFN)] 
from normal subjects as controls. Skin biopsy immu-
nostaining can help to detect aberrations in somatic 
nerves in neuropathies that were formerly classified 
as autonomic, such as Ross syndrome [8, 9]. It was [4] 
concluded that the intra-epidermal nerve fiber density 
(IENF) assessment has proven its value as a measure 
for treatment success and for follow-up in clinical tri-
als [10–13]. The EFNS Task Force developed guidelines 
for the diagnostic use of skin biopsies in peripheral 
neuropathies, published in 2005 [1]. The recommenda-
tions include the use of 3-mm punch skin biopsy from 
the distal leg, fixed in Zamboni solution and quantified 
for linear nerve fiber density in at least three consecu-
tive 50 µm sections, after PGP9.5 immunohistochemical 
or immunofluorescence staining. In the counting rules 
it was emphasized to only include IENF crossing the 
dermal-epidermal junction, while excluding secondary/
tertiary branching from the quantification [1]. From the 
perspective of use of skin biopsies in clinical trials, the 
EFNS-advised method is time-consuming and challeng-
ing for large scale batch testing in a standardized man-
ner. One way of approaching this challenge is to fully 
automate the staining procedure.
For each laboratory developed test (LDT), which aims 
to identify disease and is intended for accreditation and 
use in clinical trial settings, assay performance charac-
teristics must be established as required by CAP/CLIA 
[14] and local accreditation boards [15]. Good labora-
tory practice requires that accuracy, precision, analyti-
cal sensitivity, analytical specificity, reportable range 
and reference intervals are established [16, 17]. Biopsies 
from subjects clearly showing intra-epidermal nerve 
fiber reduction, as confirmed by conventional diagnos-
tic tools, were selected from two studies conducted ear-
lier by Ragé and colleagues [18, 19]. In the first study, 
the experimental model of reversible capsaicin-induced 
small SFN [10, 11, 20] was examined in healthy subjects 
using the laser evoked potentials (LEPs) in compari-
son to the linear nerve fiber density in skin. The second 
study aimed at investigating the diagnostic performance 
of LEPs in the assessment of small nerve fiber loss in 
asymptomatic diabetic neuropathy. From this study, 
diabetic subjects presenting with distal polyneuropa-
thy were included. In addition, skin biopsies of healthy 
subjects were studied to indicate achievable reference 
ranges, and reveal possible discrepancies and quanti-
tative caveats between the LDT and the gold standard 
method.
In this study we developed an automated PGP9.5 
LDT, to complement the gold standard, and validated its 
potential for use in large scale clinical studies.
Methods
Human samples
Fourteen skin punch biopsies are obtained from healthy 
volunteers (n = 14, age group 33–52 years). Five biopsy 
specimens, from diabetic subjects presenting poly-neu-
ropathy (n  =  5), obtained from the study described by 
Ragé and coworkers [19] were included in the study. In 
addition, two biopsy specimens obtained from healthy 
volunteers who received topical capsaicin application on 
three consecutive 24-h cycles were examined as well [18]. 
Studies were approved by the Local Ethics Committee; 
informed consent was obtained for all participants.
Skin punch biopsy processing
Skin punch biopsies (diameter 2–4 mm) were performed 
under local anesthesia at the lateral aspect of the dis-
tal leg in a clinical unit. Skin biopsies were fixed in cold 
Zamboni fixative solution (60  min at room tempera-
ture), cryopreserved in sucrose 30 % and frozen in OCT 
compound (Sakura TissueTek Europe, The Netherlands) 
as recommended by the EFNS guidelines [1, 21]. After 
freezing, tissue-blocks were stored at −80  °C prior to 
sectioning.
Accuracy confirmation by western blot analysis and double 
immunofluorescence histochemistry
Western Blot analysis was performed by SDS-page on 
cell lysates from A549 (lung carcinoma) and U87 (glio-
blastoma) cell lines exhibiting high PGP9.5 expression, to 
verify the accuracy of the rabbit polyclonal anti-human 
PGP9.5 antibody (RA95101, UltraClone Ltd., UK). Subse-
quently, western transfer of proteins was performed onto 
a transfer membrane (Immobilon FL, Li-Cor, Germany). 
After incubation of the rabbit polyclonal anti-human 
PGP9.5 antibody (1/300), visualization was performed 
using IRDye® 800CW Conjugated Goat (polyclonal) anti-
rabbit IgG antibody on the Odyssey® Infrared Imaging 
System (Li-Cor).
For double immunofluorescence histochemistry, 
16 µm-thick sections were incubated overnight at room 
temperature with a mix of primary anti-PGP9.5 (1/2000) 
and anti-βIII-Tubulin (clone 5G8, Promega Corp., USA; 
1/250) antibodies to be subsequently visualized by Cy3-
conjugated goat anti-rabbit and Alexa-488-conjugated 
goat anti-mouse antibodies (Jackson Immunoresearch 
Laboratories, Inc., USA; 1/500 and 1/100 respectively). 
Counterstain was performed using Hoechst 33342 (Invit-
rogen Molecular Probes, USA; 1/2000).
Gold standard PGP9.5 immunofluorescence according 
to EFNS (GS‑EFNS)
Three consecutive 50  µm cryosections were produced 
and collected in PBS-azide. To enhance penetration of 
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immunoreagents into 50  µm-thick sections, tissue was 
permeabilized using TritonX100 (Sigma-Aldrich, Bel-
gium; 0.1 %). Manual staining was initiated on free-float-
ing tissue sections. Incubation was performed using the 
rabbit polyclonal anti-human PGP9.5 primary antibody 
(UltraClone Ltd.; RA95101; 1/2000) overnight at room 
temperature as prescribed [1, 22]. Subsequently, the visu-
alization was established using a Cy3-labeled secondary 
goat anti-rabbit antibody (Jackson Immunoresearch Lab-
oratories; 1/500; 2  h) and counterstained with Hoechst 
33342 as described above.
Automatization of PGP9.5 Immunofluorescence staining 
on Ventana discovery XT®
Six consecutive 16  µm cryosections were produced and 
collected on dry ice. The staining protocol was custom-
programmed using RESEARCH IHC QD Map XT soft-
ware of the Discovery XT® (Ventana, USA). After loading 
the slides into the instrument, incubation was performed 
using the rabbit polyclonal anti-human PGP9.5 primary 
antibody for 2  h. Subsequently, the visualization was 
established using a Cy3-labeled secondary goat anti-rab-
bit antibody and counterstained with Hoechst 33342 as 
described above.
Quality control
For all specimens, internal controls, i.e. autonomic nerve 
fibers innervating sweat glands and m. arrector pili, were 
evaluated for positive staining and subsequent accept-
ance of each individual section. As a negative control, 
rabbit immunoglobulins (confirm negative control rabbit, 
Ventana) were used to replace the primary antibody.
Imaging and quantification
The quantification of the linear density of nerve fibers was 
performed using a conventional fluorescence microscope 
(20×–40×; Zeiss, Germany) by two readers blinded for 
treatment. Virtual images were generated using the Axio-
vision Mozaik Imaging Software (Axiovision Rel 4.8®) 
on an Axioplan 2 imaging microscope equipped with a 
motorized stage and z-stack features (Zeiss, Germany) 
and used to perform length measurements. Individual 
counts were divided by the length of the epidermis and 
expressed as mean numbers/mm (± SD).
Gold standard counting rule
The EFNS guidelines [1, 3, 23] prescribe to count each 
nerve fiber crossing the dermal-epidermal junction 
as a single unit. Nerve fibers that are approaching the 
junction without crossing it or nerve fiber fragments 
lying free in the epidermis are not enumerated, nor are 
branches.
LDT modifications to the gold standard counting rule
To critically evaluate the LDT, and the effect of reduc-
ing the section thickness, the following additions to the 
gold standard counting rule were implemented on both 
the LDT and gold standard stained slides. The epidermal 
nerve fibers, traditionally named IENF, include all nerve 
fibers crossing the dermal—epidermal junction (Fig.  1) 
as per the gold standard counting rule. In order to accu-
rately define existing discrepancies in the LDTs ability of 
visualizing the 3D-IENF network, incidence of second-
ary branching of IENF was taken into account. Therefore, 
intra-epidermal nerve fiber crossing dermal-epidermal 
junction as single fiber (IENF_Si) (Fig. 1: 1A) and intra-
epidermal nerve fiber crossing dermal-epidermal junc-
tion as fiber showing branching (IENF_Br) (Fig. 1: 1B) as 
being epidermal nerve fibers crossing the dermal-epider-
mal junction as single or branching fibers are reported. 
Since the LDT uses thinner tissue sections, and a higher 
incidence of IENF fragments is to be expected, intra-
epidermal nerve fiber fragments that do not cross the 
dermal-epidermal junction free intra-epidermal nerve 
fiber fragments (IENF_F, Fig.  1: 2A, 2B) were included. 
These fragments were not included in the EFNS guide-
lines but have been proven to be valuable [24]. Fragments 
are considered as such based on morphological charac-
teristics and an approximate minimal length of 5 µm. For 
IENF_F, the incidence of secondary branching of IENF 
was taken into account as well, resulting in IENF_FSi 
(Fig. 1: 2A) and IENF_FBr (Fig. 1: 2B). The actual number 
of branches on each nerve fiber was recorded separately. 
The total number of epidermal nerve fibers (total ENF, 
Fig. 1) represented the sum of IENF and IENF_F.
LDT method validation
Besides the confirmation that the anti-human PGP9.5 
antibody accurately detects its target, we established 
reference intervals and defined LDTs discrepancies in 
reference to the GS-EFNS (LDT modifications to the GS-
EFNS counting rule) on biopsies obtained from healthy 
subjects. Diagnostic yield and diagnostic performance 
(analytical sensitivity and specificity) were explored by 
plotting the plausibility of false positives (specificity) and 
true positives (sensitivity). The closer the ROC curve 
approaches the true positive axis, the better the perfor-
mance of the LDT (see “Statistics” section). The exami-
nation of the inter-slide stability of the GS-EFNS and 
LDT was included since this could highlight the need for 
a minimum number of serial slides to be examined. For 
each subject and each staining method three serial slide 
measurements were performed by one observer (M1, 
M2, and M3). In order to estimate the reliability of results 
obtained by independent observers, individual counts for 
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the different parameters were compared after automated 
staining of 12 randomly selected samples.
Statistics
Method comparison of the LDT and GS-EFNS was per-
formed using Bland–Altman analysis [25]. To prove a 
good agreement between the two techniques the values 
should be lumped near the 0-difference line. Statistical 
analysis was performed using a rank sum test for paired 
samples (Wilcoxon) for which p values below 0.05 were 
considered significant. Statistical analysis for assess-
ing the diagnostic yield of the LDT compared to con-
ventional diagnostic tools was performed as described 
before [19]. To explore if data obtained using the EFNS 
advised method can serve as the gold standard to define 
the diagnostic performance of the LDT on the selected 
biopsies, a one-way analysis of variance was performed 
(ANOVA). This allowed confirming that mean values 
were significantly different between control and SFN 
groups. The diagnostic performance of the LDT was 
estimated by the area under the receiver operating char-
acteristic curve (ROC) with 95 % confidence interval for 
sensitivity and specificity using De Long’s test. Inter-
observer agreement was evaluated by determining intra-
class correlation (ICC) for all parameters using the same 
raters for all measurements and consistency as type. All 
analyses were performed using MedCalc® v12.3.0.0 sta-
tistical software. Finally, a power calculation was carried 
out to determine the statistical power of this study and 
the optimal sample size for a future study using software 
package R, version 3.1.2 [26]. We performed this analysis 
using data for the total linear density of epidermal nerve 
fibers.
Results
Accuracy of the anti‑human PGP9.5 antibody
The accuracy of the rabbit polyclonal anti-human PGP9.5 
antibody was confirmed by western blot analysis on cell 
lysates from U87 and A549 cell lines. For both cell lines 
the antibody showed a band at a molecular weight of 
approximately 25  kDa (Fig.  2a), confirming the recog-
nition of PGP9.5 (27  kDa). In addition, βIII-tubulin, a 
nerve and langerhans cell-specific marker, co-localized in 
Fig. 1 Counting rules according to the GS-EFNS (1) and LDT (2). Mod-
ifications to the gold standard counting rule for intra epidermal nerve 
fibers (IENF) are depicted to include IENF fragments (_F) detected as 
single fibers (_Si) or branching (_Br). Red PGP9.5, blue Hoechst, dashed 
line dermal-epidermal junction. 1 IENF; 1A IENF_Si; 1B IENF_Br; 2 
IENF_F; 2A IENF_FSi; 2B IENF_FBr. (Scale bar 20 µm)
Fig. 2 Evaluation of antibody accuracy. a Western Blot analysis of A549 and U87 cell lines using the rabbit polyclonal anti-human PGP9.5 antibody 
(green). b Immunofluorescent staining of PGP9.5 (red) and ß-III-Tubulin (green) in the epidermis of a human skin biopsy, blue Hoechst. Asterisk Nerve 
fiber; Arrow head Langerhans-cells. (Scale bar 20 µm)
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all PGP9.5 immunoreactive structures of the epidermis 
(Fig. 2b), confirming the accuracy of the antibody.
Assessment of IENF and nerve fiber branching density 
in skin biopsies of healthy volunteers**
A significant difference existed in the ability of the LDT 
assessing IENF compared to the gold standard (p < 0.001, 
mean difference 5.8 IENF/mm), especially with regard to 
IENF_Br (p  <  0.001, mean difference 5.7 IENF_Br/mm) 
(Table 1). For IENF_Si equal results were obtained for the 
GS-EFNS and LDT (p = 0.95, mean difference 0.1 IENF_
Si/mm). Enumeration of nerve fiber fragments lying free 
in the epidermis showed a significantly higher number 
of IENF_F for the LDT compared to GS-EFNS (p = 0.01, 
mean difference −2.8 IENF_F/mm). The IENF_F were 
mainly present as single nerve fiber fragments (IENF_FSi; 
p = 0.002, mean difference −2.5 IENF_FSi/mm). Overall, 
for the total population of epidermal nerve fibers (IENF 
and IENF_F) a good agreement was reached between the 
GS-EFNS and LDT (p =  0.24, mean difference 3.0  Total 
ENF/mm) (Fig. 3; Table 1). Based on the mean difference 
and SD of both measurements, we determined that the dif-
ference between the groups equals 0.68 SD units. A power 
calculation showed that, to detect a difference in means of 
0.68 SD units, with a power of 80 %, at alpha level of 0.05, 
sample size should be at least 35 in both groups.
A significantly lower number of IENF branches was 
observed using the LDT (p  <  0.001, mean difference 
18.5  Branches/mm). Minor differences were seen for 
IENF fragment branches (p  =  0.04, mean difference 
0.2 Branches/mm) (Fig. 3; Table 1).
Diagnostic performance of the LDT for SFN
The LDT was able to distinguish between healthy and 
SFN groups (p  <  0.001) when assessing IENF linear 
density (Table  2). Importantly, the LDT reached good 
concordance with the gold standard as determined by 
Bland–Altman after assessing IENF (p > 0.42, mean dif-
ference 0.23 IENF/mm); IENF_F (p  >  0.25, mean dif-
ference −0.29 IENF/mm) and thus total ENF (p  >  0.42, 
mean difference −0.06 ENF/mm) in skin biopsies of SFN 
subjects. This clearly indicates that the LDT and GS-
EFNS are equivalent in detecting SFN (Fig.  4). A lower 
number of nerve fiber fragments lying free in the epider-
mis (IENF_F) was observed when the gold standard was 
applied (Table 2).
When secondary branching of nerve fibers was taken 
into account, a good agreement was found for all param-
eters evaluated, showing mean differences less than 0.5/
mm. Nevertheless, lower scoring for IENF without sec-
ondary branching (mean difference of −0.16 IEFN_Si/
mm) (p = 0.42) at one hand and a higher assessment of 
IENF showing secondary branching (mean difference of 
0.39 IENF_Br/mm) (p  =  0.09) was seen using the gold 
standard, as was the case in the biopsies from the healthy 
volunteers (Table 2).
Diagnostic yield of the LDT for SFN
ANOVA analysis confirmed that GS-EFNS can serve as 
gold standard for the diagnosis of SFN when performed 
in our lab. Data were grouped using the knowledge of the 
disease states of the different subjects. A significant dif-
ference was observed for IENF between healthy and SFN 
groups (p < 0.001, F-ratio 87.5) (Fig. 5a). Therefore, GS-
EFNS results could be used to determine the expected 
diagnosis to be obtained using the LDT (ROC, Fig. 5b).
As IENF density, determined using the LDT, is signifi-
cantly lower compared to the GS-EFNS, the total popu-
lation of epidermal nerve fibers counted (Total ENF/
mm) was used as cut-off. The average linear density in 
the tested control group was 15.45 ± 4.43 Total ENF/mm 
(Table 1), therefore the lower cut-off used was 11.02 Total 
ENF/mm. Using this cut-off to classify data obtained with 
the LDT, a sensitivity of 80 % and specificity of 64 % was 
reached with an area under the ROC curve of 0.72 and 
p = 0.031.
Inter‑slide stability and robustness
For all parameters and both staining methods, mean dif-
ferences between repeated measures (M1, 2, 3) observed 
were very small, not exceeding 1 nerve fiber/mm as 
Table 1 Comparing GS-EFNS and  LDT for  assessing nerve 
fiber density in skin biopsies of healthy volunteers
ENF epidermal nerve fiber, GS-EFNS gold standard method according to EFNS; 
IENF intra-epidermal nerve fiber, IENF_Si intra-epidermal nerve fiber crossing 
dermal-epidermal junction as single fiber, IENF_Br intra-epidermal nerve fiber 
crossing dermal-epidermal junction as fiber showing branching, IENF_F nerve 
fiber fragment lying free in epidermis, IENF_FSi nerve fiber fragment lying free 
in epidermis as single fragment, IENF_FBr nerve fiber fragment lying free in 
epidermis showing branching, LDT laboratory developed test, Sec secondary
GS‑EFNS LDT Mean diff P
IENF (#/mm) 11.47 ± 2.67 5.65 ± 1.93 5.8 <0.001
 IENF_Si (#/mm) 4.45 ± 1.06 4.31 ± 1.59 0.1 0.95
 IENF_Br (#/mm) 7.02 ± 2.23 1.34 ± 0.51 5.7 <0.001
 Sec branching  
(#/IENF_Br)
3.17 ± 0.26 2.39 ± 0.40 <0.001
 Sec branching  
(#/mm)
22.04 ± 7.92 3.56 ± 1.44 18.5 <0.001
IENF_F (#/mm) 3.98 ± 2.25 6.77 ± 2.89 −2.8 0.01
 IENF_FSi (#/mm) 2.36 ± 1.10 4.86 ± 2.18 −2.5 0.002
 IENF_FBr (#/mm) 1.62 ± 1.28 1.91 ± 0.86 −0.3 0.36
 Sec branching  
(#/IENF_FBr)
2.52 ± 0.57 2.13 ± 0.23 0.04
 Sec branching  
(#/mm)
4.42 ± 3.91 4.26 ± 1.88 0.01
Total ENF (#/mm) 15.45 ± 4.43 12.45 ± 4.33 3.0 0.24
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determined by Bland–Altman analysis (Table  3). Both 
techniques showed a success rate exceeding 95 % with no 
failure and thus no exclusion of samples when the LDT is 
applied.
Inter‑observer agreement
Overall, the inter-reader agreement can be considered 
excellent with ICC values ranging from 0.93 to 0.99 
(Table 4) for all linear density values enumerated on LDT 
stained samples.
Discussion
As proven by multiple investigators, skin biopsies are 
excellent tools to investigate the nerve fiber endings in 
the epidermis [1–7]. Since the early nineties, the neu-
ronal biomarker PGP9.5 has been regarded as the most 
accurate for the visualization of epidermal nerves [22, 
Fig. 3 PGP9.5 Immunofluorescence in skin biopsy of a healthy volunteer. PGP9.5 immunofluorescence using the gold standard (GS-EFNS: a1) 
method and laboratory developed test (LDT: b1) was performed as described. a2 and b2 show the single channel image of PGP9.5 immunofluores-
cence (red). Red PGP9.5, Blue Hoechst. (Scale bar 50 µm)
Table 2 Comparing GS-EFNS and  LDT for  assessing nerve 
fiber density in skin biopsies of SFN patients
Diff difference, ENF epidermal nerve fiber, GS-EFNS gold standard method 
according to EFNS, IENF intra-epidermal nerve fiber, IENF_Si intra-epidermal 
nerve fiber crossing dermal-epidermal junction as single fiber, IENF_Br intra-
epidermal nerve fiber crossing dermal-epidermal junction as fiber showing 
branching, IENF_F nerve fiber fragment lying free in epidermis, IENF_FSi nerve 
fiber fragment lying free in epidermis as single fragment, IENF_FBr nerve fiber 
fragment lying free in epidermis showing branching, LDT laboratory developed 
test
GS‑EFNS LDT Mean diff. P
IENF 1.12 ± 1.65 0.89 ± 1.35 0.23 0.42
 IENF_Si 0.55 ± 0.56 0.71 ± 0.95 −0.16 0.42
 IENF_Br 0.57 ± 1.16 0.18 ± 0.43 0.39 0.09
IENF_F 0.38 ± 0.84 0.66 ± 1.16 −0.29 0.25
 IENF_FSi 0.23 ± 0.49 0.46 ± 0.76 −0.23 0.30
 IENF_FBr 0.15 ± 0.35 0.21 ± 0.41 −0.06 0.17
Total ENF 1.50 ± 2.46 1.56 ± 2.48 −0.06 0.42
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27]. As the use of this technique grew for the diagnosis 
of SFN, the need for guidelines and standardization grew 
accordingly. In 2005, the members of the EFNS indicated 
the advised procedure for the assessment of epidermal 
nerve fiber density [1]. The gold standard was described 
in detail [23], and implemented successfully in special-
ized laboratories over the world. Other investigators used 
the IENF density as a reference in experimental disease 
progression studies [10, 11], and early detection of SFN 
in diabetics [12, 13], and compared its accuracy to that of 
conventional diagnostic tools. Nevertheless, this method 
is a labor intense, manual staining procedure, requiring 
high methodological skills and training, and is therefore 
prone to human error when applied in conventional diag-
nostic laboratories. The use of uniform outcome meas-
ures in peripheral neuropathies has been commended 
recently, to enable comparison between studies [28].
In this study, we explored whether a gold standard-
related LDT could be developed, with decreased labor 
and increase of standardization as primary goals, by 
automating the staining method. Automated slide stain-
ing use implied a significant decrease in section thickness 
Fig. 4 PGP9.5 Immunofluorescence in skin biopsy of a SFN patient. PGP9.5 immunofluorescence using the gold standard (GS-EFNS: a) and labora-
tory developed test (LDT: b) was performed as described. Red PGP9.5, Blue Hoechst. (Scale bar 50 µm)
Fig. 5 Diagnostic performance of the LDT for SFN. a Multiple comparisons graphic, retrieved after one-way analysis of variance (ANOVA) of IENF 
data obtained using gold standard staining (GS-EFNS) of skin biopsies from healthy volunteers and SFN patients (*** p < 0.001). b Diagnostic perfor-
mance of LDT for variable Total ENF/mm: area under the ROC curve of 0.72 and p = 0.031 with a sensitivity of 80 % and specificity of 64 %. The lower 
average Total ENF linear density value in the tested control group, 11.02 Total ENF/mm, was used as cut-off
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of the skin biopsies. The choice of using 16 µm-thick sec-
tions was driven by the work of Torres and colleagues 
[29] and Hedreen [30], both describing that thicker sec-
tions mounted on glass slides can present suboptimal 
penetration of immuno-reagents into the tissue, leading 
to a lost-cap phenomenon. The use of thinner sections 
for subsequent IENF assessment has been proven valu-
able by different groups, not only for SFN detection, but 
also the study of multiple nerve markers including ion 
channels and receptors in the same biopsies and the pro-
gression and/or follow up of disease [6, 22, 31–36].
The design of the LDT and its subsequent validation 
was based on requirements of CAP, CLIA and a local 
accreditation board (BELAC) to be able to introduce the 
LDT in large scale batch testing required for clinical trial 
testing. We explored whether the LDT could meet the 
needs for both an accredited laboratory and the pharma-
ceutical industry, while maintaining a good concordance 
with the gold standard. In this study, fluorescence detec-
tion was preferred to allow future advanced imaging as 
described recently [37, 38]. Published data showing good 
concordance between fluorescent and bright-field assess-
ment of IENF in the diagnosis of SFN justifies this choice 
[39]. Implementation of fluorescence in IENF assessment 
additionally helps with the ease of studying multiple tar-
gets in a single tissue section.
Accuracy of the PGP9.5 antibody was confirmed in our 
hands, being concordant with results described by groups 
of Brichory, Krimm, Tokumaru and Barrachina [40–43].
Once good accuracy was confirmed, the automated 
user-defined assay performed on the Discovery XT® was 
challenged against the gold standard using skin biopsies 
of healthy volunteers. We first demonstrated that perfor-
mance of the assay in our accredited laboratory accord-
ing the EFNS advised gold standard method meets all 
criteria. A good concordance was reached with published 
normative values (9.8–12.4 IENF/mm for female subjects 
in the age group of 33–52) as described by Lauria and 
co-workers [23] when assessing IENF in skin biopsies of 
predominantly female subjects included in this study. The 
gold standard could distinguish between healthy and SFN 
subjects with high significance and served as a reference.
When exploring the IENF density as assessed by the 
LDT, results clearly indicated that the LDT’s ability to 
visualize IENF in skin of healthy subjects is considerably 
lower compared to the gold standard, whereas a good 
concordance was reached when both IENF and IENF 
fragments were considered (total ENF). A higher number 
of IENF and visualization of their branches using the gold 
standard is in line with the increased occurrence of nerve 
fiber fragments observed in the thinner sections of the 
LDT. Considering the threefold decrease in section thick-
ness, one would expect to have a threefold decrease in 
Table 3 Assessment of  the inter-slide stability for  scoring 
PGP9.5 using Bland–Altman analysis for  the comparison 
of GS-EFNS and LDT
Diff difference, ENF epidermal nerve fiber, GS-EFNS gold standard method 
according to EFNS, IENF intra-epidermal nerve fiber, IENF_Si intra-epidermal 
nerve fiber crossing dermal-epidermal junction as single fiber, IENF_Br intra-
epidermal nerve fiber crossing dermal-epidermal junction as fiber showing 
branching, IENF_F nerve fiber fragment lying free in epidermis, IENF_FSi nerve 
fiber fragment lying free in epidermis as single fragment, IENF_FBr nerve fiber 
fragment lying free in epidermis showing branching, LDT laboratory developed 
test
Mean diff (#/mm)
GS-EFNS
 M1–M2
  IENF_Si −0.3
  IENF_Br −0.3
  IENF_FSi 0.2
  IENF_FBr 0.4
  IENF_Si −0.3
 M1–M3
  IENF_Si 0.2
  IENF_Br 0.5
  IENF_FSi 0.5
  IENF_FBr 0.2
LDT
 M1–M2
  IENF_Si −0.9
  IENF_Br 0
  IENF_FSi −0.3
  IENF_FBr −0.2
 M1–M3
  IENF_Si −0.8
  IENF_Br 0.5
  IENF_FSi −0.6
  IENF_FBr 0.2
Table 4 Inter-observer agreement when  determining 
nerve fiber density in  skin biopsies of  SFN patients using 
LDT
ENF epidermal nerve fiber GS-EFNS: gold standard method according to EFNS, 
ICC itra-class correlation, IENF intra-epidermal nerve fiber, IENF_Si intra-
epidermal nerve fiber crossing dermal-epidermal junction as single fiber, 
IENF_Br intra-epidermal nerve fiber crossing dermal-epidermal junction as 
fiber showing branching, IENF_F ierve fiber fragment lying free in epidermis, 
IENF_FSi ierve fiber fragment lying free in epidermis as single fragment, IENF_FBr 
nerve fiber fragment lying free in epidermis showing branching, LDT laboratory 
developed test, SFN small fiber neuropathy
ICC
IENF 0.97
 IENF_Si 0.98
 IENF_Br 0.93
IENF_F 0.99
 IENF_FSi 0.99
 IENF_FBr 0.97
Total ENF 0.99
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linear densities of the evaluated parameters. As we found 
an approximate twofold decrease for healthy subjects and 
1.25-fold decrease in SFN subjects compared to the GS, 
one must consider that nerve fibers might be included 
more than once in the counting strategy when the LDT is 
applied. Nevertheless, the diagnostic performance of the 
LDT was equal to that of the gold standard in discrimi-
nating healthy from SFN subjects with high significance 
when IENF was assessed.
Additionally, an excellent agreement between both 
staining methods was found for all parameters quantified 
in biopsies from subjects with (experimental) SFN. Both 
the number of IENF, IENF fragments and their secondary 
branching could be equally visualized. In addition, pre-
viously published work documented concordance of the 
LDT’s outcome with TRPV1 staining performed in a dif-
ferent laboratory. Results describing a functional recov-
ery, prior to morphological recovery in a time course 
study after capsaicin was applied, were consistent with 
findings of other groups [18].
When the diagnostic yield of the LDT was measured, 
we concluded that IENF and IENF fragments are both 
mandatory to be included in enumeration when the LDT 
is applied. IENF assessment alone lacked concordance 
with the gold standard method. When the total number 
of nerve fibers (IENF and IENF fragments) was consid-
ered, the LDT reached relatively good concordance with 
the gold standard, with strong sensitivity and specificity. 
Finally, the LDT showed an excellent robustness and an 
excellent inter-observer concordance.
Conclusions
To conclude, in this proof of principle study we evalu-
ated a standardized, on-slide, automated staining proce-
dure for the assessment of the linear density of epidermal 
nerve fibers. This method demonstrated an equal perfor-
mance to the gold standard in distinguishing SFN from 
healthy subjects. By automation and on-slide application 
of staining thinner sections, labor, variation of results 
induced by human manipulation and differential pen-
etration of immunoreagents are drastically reduced. The 
decreased sensitivity, however, for detecting the complex 
three-dimensional branching network of epidermal nerve 
fibers is important to consider, as depletion of more distal 
axons is likely to be an early feature of dying back neu-
ropathies. In this perspective, the appearance of collateral 
sprouting, typical for regenerating nerve fibers [44], and 
the LDT’s capability of discriminating that from nor-
mal epidermal nerve fibers, needs further investigation. 
The same applies for the risk of missing the SFN status 
in older patients. Effectiveness in detection of important 
cutaneous nerve abnormalities, such as axonal swellings, 
crawlers and sprouts, by the LDT need to be examined 
as well [45]. Formation of a larger cohort, minimally 35 
per group as determined by power calculation and inclu-
sion of a solid age and gender distribution is required to 
determine reference values and to determine whether the 
dynamic range of the LDT is acceptable. Power calcula-
tion showed that the current study design only offers 29 % 
power to detect a difference in means of the calculated 
SD units. Since epidermal nerve fiber fragments need to 
be included in the now more laborious counting strategy, 
compatibility of this technique with the semi-automated 
analysis recently presented [38] should be investigated 
as well. This technique could lead to high reproducibility 
of counting within and between neuropathological insti-
tutes. Introducing proficiency testing and dermal nerve 
quantification [46] could benefit in standardization.
Full automation of the staining procedure could be val-
uable and lead to accessible, stable and reliable testing in 
clinical trials and diagnostics for clear SFN detection. A 
number of limitations however exist for this LDT which 
require expert-evaluation in a larger cohort.
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